Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and safety of tocilizumab in active rheumatoid arthritis after 4 and 24 weeks
2008-000105-11Phase 3Completed
- Sponsor
- Roche
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: DAS28 low disease activity at week 24. Started May 2008; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-000105-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000105-11.